Your browser doesn't support javascript.
loading
In Silico Prediction of Plasmodium falciparum Cytoadherence Inhibitors That Disrupt Interaction between gC1qR-DBLß12 Complex.
Hafiz, Abdul; Bakri, Rowaida; Alsaad, Mohammad; Fetni, Obadah M; Alsubaihi, Lojain I; Shamshad, Hina.
Afiliación
  • Hafiz A; College of Medicine, Umm AL Qura University, Makkah 21955, Saudi Arabia.
  • Bakri R; College of Medicine, Umm AL Qura University, Makkah 21955, Saudi Arabia.
  • Alsaad M; College of Medicine, Umm AL Qura University, Makkah 21955, Saudi Arabia.
  • Fetni OM; College of Medicine, Umm AL Qura University, Makkah 21955, Saudi Arabia.
  • Alsubaihi LI; King Faisal Hospital, Makkah 24236, Saudi Arabia.
  • Shamshad H; College of Medicine, Umm AL Qura University, Makkah 21955, Saudi Arabia.
Pharmaceuticals (Basel) ; 15(6)2022 May 31.
Article en En | MEDLINE | ID: mdl-35745611
Malaria causes about half a million deaths per year, mainly in children below 5 years of age. Cytoadherence of Plasmodium falciparum infected erythrocytes in brain and placenta has been linked to severe malaria and malarial related deaths. Cytoadherence is mediated by binding of human receptor gC1qR to the DBLß12 domain of a P. falciparum erythrocyte membrane protein family 1 (PfEMP1) protein. In the present work, molecular dynamic simulation was extensively studied for the gC1qR-DBLß12 complex. The stabilized protein complex was used to study the protein-protein interface interactions and mapping of interactive amino acid residues as hotspot were performed. Prediction of inhibitors were performed by using virtual protein-protein inhibitor database Timbal screening of about 15,000 compounds. In silico mutagenesis studies, binding profile and protein ligand interaction fingerprinting were used to strengthen the screening of the potential inhibitors of gC1qR-DBLß12 interface. Six compounds were selected and were further subjected to the MAIP analysis and ADMET studies. From these six compounds, the compounds 3, 5, and 6 were found to outperform on all screening criteria from the rest selected compounds. These compounds may provide novel drugs to treat and manage severe falciparum malaria. Additionally. the identified hotspots can be used in future for designing novel interventions for disruption of interface interactions, such as through peptides or vaccines. Futher in vitro and in vivo studies are required for the confirmation of these compounds as potential inhibitors of gC1qR-DBLß12 interaction.
Palabras clave

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Tipo de estudio: Prognostic_studies / Risk_factors_studies Idioma: En Revista: Pharmaceuticals (Basel) Año: 2022 Tipo del documento: Article País de afiliación: Arabia Saudita Pais de publicación: Suiza

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Tipo de estudio: Prognostic_studies / Risk_factors_studies Idioma: En Revista: Pharmaceuticals (Basel) Año: 2022 Tipo del documento: Article País de afiliación: Arabia Saudita Pais de publicación: Suiza